Overview

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Status:
Not yet recruiting

Trial end date:
2021-06-30

Target enrollment:

Participant gender:

Summary

This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.

Phase:

Early Phase 1

Details

Lead Sponsor:

Rutgers, The State University of New Jersey

Collaborator:

National Cancer Institute (NCI)

Treatments:

Loratadine